Asahi Kasei, GlaxoSmithKline and Johnson & Johnson helped the respiratory disease drug developer boost its overall funding to $150m.

Pulmocide, a UK-based developer of therapies for serious acute and chronic respiratory diseases, secured $92m in series C commitments today from investors including pharmaceutical firms Asahi Kasei, GlaxoSmithKline and Johnson & Johnson.

Investment company Jeito Capital led the oversubscribed round, which also attracted F-Prime Capital, a subsidiary of investment and financial services group Fidelity, as well as IP Group, Adjuvant Capital, SV Health Investors and Longwood Fund.

GlaxoSmithKline and Johnson & Johnson invested through SR One and Johnson & Johnson…